Integrated Quantitative Investments LLC Makes New $1.15 Million Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Integrated Quantitative Investments LLC acquired a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 31,900 shares of the medical device company's stock, valued at approximately $1,149,000.

Several other large investors have also recently added to or reduced their stakes in the business. AlphaQuest LLC raised its holdings in Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after acquiring an additional 541 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in shares of Tandem Diabetes Care by 195.8% in the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after purchasing an additional 748 shares in the last quarter. Assetmark Inc. lifted its position in shares of Tandem Diabetes Care by 77.5% during the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock worth $44,000 after purchasing an additional 535 shares during the last quarter. McIlrath & Eck LLC acquired a new position in shares of Tandem Diabetes Care during the third quarter worth $52,000. Finally, Smartleaf Asset Management LLC increased its holdings in Tandem Diabetes Care by 163.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after buying an additional 1,101 shares during the last quarter.

Tandem Diabetes Care Stock Performance

Shares of TNDM stock traded up $0.45 during mid-day trading on Wednesday, hitting $16.82. The stock had a trading volume of 713,404 shares, compared to its average volume of 1,512,025. Tandem Diabetes Care, Inc. has a fifty-two week low of $15.75 and a fifty-two week high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The company's 50-day simple moving average is $25.16 and its 200-day simple moving average is $31.59. The firm has a market cap of $1.12 billion, a PE ratio of -8.71 and a beta of 1.52.

Remove Ads

Insider Buying and Selling at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the business's stock in a transaction dated Friday, March 7th. The stock was acquired at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on TNDM. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $22.00 price objective (down from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Robert W. Baird cut their price objective on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Morgan Stanley downgraded shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $45.00 to $22.00 in a research report on Wednesday, March 5th. Sanford C. Bernstein cut shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Finally, The Goldman Sachs Group dropped their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $45.38.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.